Clinical Trial Search

Primary: Total Positive and Negative Syndrome Scale (PANSS) Score Between Baseline and 24 Weeks. — 89.0; 89.7; 80.0; 80.8 score on a scale

Primary: Cognition Measured by AX-Continuous Performance Test (AX-CPT) D-prime Score — 2.7; 2.5; 2.3; 3.2 d prime score — p=<0.016

Primary: Change From Baseline in HbA1c — -1.59; -0.69 percentage of HbA1c — p=<0.0001

Primary: Platelet Reactivity Measured as PRU — 154.5; 23; 104 PRU

Primary: Antiviral Activity at Week 48 of DTG+3TC Among ART-naïve HIV Patients With a CD4 Count ≤200 Cells/mm3. — 125; 62 Participants

Primary: Percentage of Participants Achieving ≥ 90% Reduction From Baseline in Eczema Area and Severity Index Score (EASI 90) at Week 24 — 74.6; 48.1; 68.5; 29.3 percentage of…

Primary: Proportion of Patients With Neutropenia Compared to Historical Controls — 0; 30 Participants — p=0.02

Primary: Time to "Fitness for Discharge" From the Recovery Room — 165.64; 154.60 Minutes

Primary: Change is 24-hour Systolic Blood Pressure From Baseline to 4 Weeks — -5.9; -7.5; -8.4 mmHg

Primary: Surgical Blood Loss — 761; 691 ml

Primary: Change in Expanded Adult ADHD Investigator Symptom Rating Scale (AISRS) Total Score — 24.1 score on a scale

Primary: Cumulative Intra- and Postoperative Opioid Consumption — 0.209; 0.188 IV morphine milligram equivalent/kg — p=0.123

Primary: Number of Participants Infected With Plasmodium Falciparum (P. Falciparum) by World Health Organisation (WHO) Age Group — 98; 148; 82; 46 Participants

Primary: Number of Participants With Adverse Events of Special Interest (AESIs) Through Week 52 — 0; 0; 2; 0 Participants

Primary: Patient-Reported Pain Intensity and Interference Score — 4.16; 3.86; 3.57; 4.72 score on a scale